The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Next Oncology; START
Leadership - Symphogen
Consulting or Advisory Role - Abbvie (Inst); AbGenomics International (Inst); Adagene (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Agenus (Inst); Agenus (Inst); Aro Biotherapeutics (Inst); Ascentage Pharma (Inst); Aximmune (Inst); Bayer (Inst); Bioinvent (Inst); Boston Biomedical (Inst); Cello Health (Inst); EMD Serono (Inst); Forbius (Inst); Gilde Healthcare (Inst); HBM Partners (Inst); Immunome (Inst); Immunome (Inst); Mekanistic Therapeutics (Inst); Menarini (Inst); Mirati Therapeutics (Inst); Nanobiotix (Inst); NBE Therapeutics (Inst); Nuvalent, Inc. (Inst); OSI Pharmaceuticals (Inst); Pelican Therapeutics (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Pierre Fabre (Inst); Ridgeway Therapeutics (Inst); Roche/Genentech (Inst); Scientex (Inst); Seagen (Inst); Sequenom (Inst); Sesen Bio (Inst); Seven and Eight Biopharmaceuticals (Inst); Symphogen (Inst); Syneos Health (Inst)
Research Funding - Abbvie (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aminex (Inst); Amphivena Therapeutics (Inst); Arrys Therapeutics (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Basilea (Inst); Boehringer Ingelheim (Inst); CStone Pharmaceuticals (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Inhibrx (Inst); Innate Pharma (Inst); Janssen Research & Development (Inst); K-Group Beta (Inst); Kechow Pharma (Inst); Kiromic (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); naturewise (Inst); NextCure (Inst); Nitto BioPharma (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Samumed (Inst); Seagen (Inst); Seven and Eight Biopharmaceuticals (Inst); Sound Biologics (Inst); Spring Bank (Inst); Sunshine Guojian (Inst); Symphogen (Inst); Syndax (Inst); Synthorx (Inst); Tizona Therapeutics, Inc. (Inst); zymeworks (Inst)
 
Research Funding - Abbvie
A phase I study of CD40 agonist ABBV-927 plus OX40 agonist ABBV-368 with or without the PD-1 inhibitor budigalimab in patients with advanced solid tumors.
 
John D. Powderly
Employment - BioCytics; Carolina BioOncology Institute
Leadership - BioCytics; Carolina BioOncology Institute
Stock and Other Ownership Interests - BioCytics; Bluebird Bio; Carolina BioOncology Institute; Juno Therapeutics; Kite, a Gilead company; Lion Biotechnologies; ZIOPHARM Oncology
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Curis; Genentech/Roche; TopAlliance BioSciences Inc
Speakers' Bureau - Bristol-Myers Squibb; Dendreon; Genentech/Roche; Merck
Research Funding - Abbvie; Alkermes; Arcus Biosciences; AstraZeneca/MedImmune; Atreca (Inst); Bristol-Myers Squibb; Corvus Pharmaceuticals; Curis; EMD Serono; FLX Bio; Genentech/Roche; Incyte; Lilly/ImClone; Macrogenics; Seagen; Tempest Therapeutics; Top Alliance BioScience
Patents, Royalties, Other Intellectual Property - BioCytics is developing intellectual property for cellular immunotherapy
Other Relationship - Ongoing discussions with potential future biopharma and biotech for Human Applications Lab sponsored projects
 
Anthony Tolcher
No Relationships to Disclose
 
Patricia LoRusso
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Abbvie; Agenus; Agios; Astellas Pharma; AstraZeneca; Black Diamond Therapeutics; Cybrexa Therapeutics; CytomX Therapeutics; EMD Serono; Five Prime Therapeutics; Genentech; Genmab; GlaxoSmithKline; Halozyme; I-MAB; Immunome; IQvia; Macrogenics; Pfizer; QED Therapeutics; Roche/Genentech; Salarius Pharmaceuticals; Shattuck Labs; Silverback Therapeutics; Sotio; Takeda; Trial to Reduce IDDM in the Genetically at Risk (TRIGR); TYME
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Genentech
 
Martha Elizabeth Blaney
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Daniel Dacosta
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
William R Henner
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Michael Anthony McDevitt
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Kathy D. Miller
No Relationships to Disclose
 
Talia Golan
Honoraria - MSD; Rafael Pharmaceuticals
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; MSD; Teva
Speakers' Bureau - Abbvie; AstraZeneca
Research Funding - AstraZeneca (Inst); MSD (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD